Linagliptin and Post procedural infection - a phase IV clinical study of FDA data

Summary:

Post procedural infection is reported as a side effect among people who take Linagliptin (linagliptin), especially for people who are female, 60+ old, also take Furosemide, and have Hiv infection.

The phase IV clinical study analyzes which people have Post procedural infection when taking Linagliptin. It is created by eHealthMe based on reports of 8,096 people who have side effects when taking Linagliptin from the FDA, and is updated regularly.

What is Linagliptin?

Linagliptin has active ingredients of linagliptin. eHealthMe is studying from 8,112 Linagliptin users. Check the latest studies of Linagliptin.

What is Post procedural infection?

Post procedural infection is found to be associated with 592 drugs and 565 conditions by eHealthMe. Check the latest studies of Post procedural infection.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

8,096 people reported to have side effects when taking Linagliptin.
Among them, 29 people (0.36%) have Post procedural infection.

Could Linagliptin cause Post procedural infection?

Among these 29 people:

What is the gender of people who have Post procedural infection when taking Linagliptin? *

female: 100 %
male: 0.0 %

What is the age of people who have Post procedural infection when taking Linagliptin? *

What are other drugs people take besides Linagliptin? *

Furosemide: 26 people, 89.66%
Pantoprazole: 25 people, 86.21%
Fluoxetine: 22 people, 75.86%
Dovato: 21 people, 72.41%
Lamivudine: 13 people, 44.83%
Tivicay: 11 people, 37.93%
Fluoxetine Hydrochloride: 3 people, 10.34%
Atorvastatin Calcium: 3 people, 10.34%
Dolutegravir: 2 people, 6.90%
Candesartan Cilexetil: 1 person, 3.45%

What are other side effects people have besides Post procedural infection? *

Staphylococcal Sepsis (blood infection by an infection with staphylococcus bacteria): 25 people, 86.21%
Urinary Tract Infection: 25 people, 86.21%
Infection: 4 people, 13.79%
Vaginal Infection: 1 person, 3.45%
Endometriosis (appearance of endometrial tissue outside the uterus and causing pelvic pain): 1 person, 3.45%
Blood Glucose Increased: 1 person, 3.45%
Breast Cancer Female: 1 person, 3.45%
Cardiac Failure: 1 person, 3.45%
Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 3.45%
Diabetes: 1 person, 3.45%

What are the existing conditions these people have? *

Hiv Infection: 22 people, 75.86%
Type 2 Diabetes: 1 person, 3.45%
Systemic Lupus Erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue): 1 person, 3.45%
Psoriasis (immune-mediated disease that affects the skin): 1 person, 3.45%
Migraine (headache): 1 person, 3.45%

* Approximation only. Some reports may have incomplete information.

Do you take Linagliptin and have Post procedural infection?

- Check whether Post procedural infection is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Linagliptin:

Linagliptin (8,112 reports)

Browse all side effects of Linagliptin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Post procedural infection:

Post procedural infection (592 drugs)

Browse all the conditions that are associated with Post procedural infection:

Post procedural infection (565 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on linagliptin (the active ingredients of Linagliptin) and Linagliptin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.